GSK to acquire U.S.-based BELLUS Health for $14.75 per share
April 18, 2023 at 02:33 AM EDT
GSK said the deal will provide access to camlipixant, a treatment for refractory chronic cough currently in phase III development.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.